Skip to Content

Menactra Approval History

  • FDA approved: Yes (First approved January 14th, 2005)
  • Brand name: Menactra
  • Generic name: meningococcal conjugate vaccine
  • Company: Sanofi Pasteur
  • Treatment for: Meningococcal Meningitis Prophylaxis

Menactra (meningococcal conjugate vaccine) is a quadrivalent conjugate vaccine indicated for the prevention of meningococcal disease.

Development History and FDA Approval Process for Menactra

Apr 25, 2011Approval FDA Approves Menactra to Prevent Meningococcal Disease in Infants and Toddlers
Jan 17, 2005Approval Menactra Sanofi Pasteur - Treatment for Protection Against Meningococcal Disease
Sep 22, 2004Advisory Panel Recommends FDA Licensure of Aventis' Menactra Vaccine for Protection Against Meningococcal Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.